Algeta and Bayer to present analysis from Alpharadin clinical program at 35th ESMO Congress
(Thomson Reuters ONE) -
Oslo, Norway, 8 October 2010 - Algeta ASA (OSE: ALGETA), the focused oncology
company, announces that analysis of clinical data from previous studies in its
phase I and phase II clinical programs with Alpharadin will be presented at the
2010 ESMO Congress, in Milan, Italy (8-12 October).
Alpharadin (radium-223 chloride) is being developed by Algeta and Bayer Schering
Pharma AG and is in a global phase III clinical trial (ALSYMPCA) to treat bone
metastases resulting from castration-resistant prostate cancer (CRPC). The
primary endpoint of the Phase III trial is overall survival. Alpharadin is a
first-in-class alpha-pharmaceutical that in Phase II trials showed a
statistically significant improvement in overall survival compared to placebo, a
consistent improvement in disease-related biomarkers and pain, and a favorable
side-effect profile.
Details of the presentation are as follows, and copies will be available from
www.algeta.com:
ESMO Congress: Abstract No. 887P - Radium-223 chloride, a novel, highly targeted
alpha-pharmaceutical for treatment of bone metastases from castration-resistant
prostate cancer (CRPC): hematologic and safety profile with repeated dosing.
Presented by: Professor Chris Parker (Institute of Cancer Research and Royal
Marsden Hospital, Sutton, UK)
Poster Presentation I
Saturday, October 9, 1:00 pm - 2:00 pm CET
Location: Hall 3
###
For further information, please contact:
For Algeta:
Andrew Kay, CEO +47 2300 7990 / +47 4840 1360 (mob)
Gillies O'Bryan-Tear, CMO +47 23 00 7824 / +47 4804 1411 (mob)
Øystein Soug, CFO +47 2300 7990 / +47 9065 6525 (mob)
post(at)algeta.com
International media enquiries: +44 207 638 9571
Mark Swallow/Helena Galilee/David Dible mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries: +1 646 378 2928
Jessica Lloyd jlloyd(at)troutgroup.com
The Trout Group
About Algeta
Algeta is a focused oncology company developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (based on radium-223) is a first-in-class,
highly targeted alpha-pharmaceutical under clinical evaluation to improve
survival in patients with bone metastases from advanced cancer. Its localized
action helps preserve the surrounding healthy tissue thereby limiting side-
effects.
The development of bone metastases represents a serious development for cancer
patients as they are associated with a dramatic decline in patient health and
quality of life, ultimately leading to death. Bone metastases represent a major
unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g.
prostate, breast and lung.
Alpharadin is being developed under a development and commercialization
agreement with Bayer Schering Pharma AG, a major pharmaceutical company, and is
in a global phase III clinical trial (ALSYMPCA) to treat bone metastases
resulting from castration-resistant prostate cancer (CRPC). Alpharadin is also
under investigation in phase II clinical trials as a potential new treatment for
bone metastases in endocrine-refractory breast cancer patients, and in a phase
I/IIa trial in combination with docetaxel chemotherapy in for bone metastases
CRPC patients.
Algeta also aims to develop a future pipeline of tumor-targeting alpha-
pharmaceutical candidates based on the alpha particle emitter thorium-227,
through selective in-licensing and/or acquiring innovative technologies and
tumor-targeting molecules.
The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta
listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
###
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1450033]
Algeta and Bayer to present analysis from Alpharadin clinical program at 35th ESMO Congress:
http://hugin.info/134655/R/1450033/391664.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 08.10.2010 - 08:31 Uhr
Sprache: Deutsch
News-ID 44641
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 192 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta and Bayer to present analysis from Alpharadin clinical program at 35th ESMO Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
